GlassScriptPhysician profile
Rola M Khedraki
NPI 1326466707
$82,234.65
in general payments reported to CMS, 2019-2025
30 companies · $54K in 2025
The $54K reported for 2025 was more than what 93% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,332 · 2020: $214 · 2021: $457 · 2022: $2,216 · 2023: $1,496 · 2024: $23K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Consulting Fee: $22K · Travel and Lodging: $5,473 · Food and Beverage: $4,666 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,975.50 |
| Consulting Fee | $21,883.07 |
| Travel and Lodging | $5,473.30 |
| Food and Beverage | $4,665.77 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $34,348.25 | 2019-2025 | Amvuttra, Onpattro |
| Astrazeneca Pharmaceuticals LP | $15,548.17 | 2020-2025 | Wainua |
| Bridgebio Pharma, INC. | $13,065.57 | 2025 | Attruby |
| Pfizer INC. | $5,592.53 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $4,407.10 | 2025 | Assure Wcd |
| Abbott Laboratories | $2,732.89 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Mitraclip |
| Impulse Dynamics (USA) INC. | $1,809.53 | 2022-2025 | Optimizer |
| Abiomed | $1,209.60 | 2022-2025 | Impella |
| Boston Scientific Corporation | $544.25 | 2019-2024 | Watchman, Lux-Dx Insertable Cardiac Monitor |
| Medtronic Vascular, INC. | $471.43 | 2019-2020 | |
| Cardiac Dimensions, INC. | $438.29 | 2023-2024 | |
| Penumbra, INC. | $300.39 | 2021-2024 | Indigo System |
| Medtronic, INC. | $292.64 | 2021-2023 | Micra |
| Actelion Pharmaceuticals US, INC. | $270.97 | 2022-2025 | Uptravi, Opsumit |
| Cvrx, INC. | $246.75 | 2024-2025 | Barostim Neo System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $176.12 | 2021-2024 | |
| United Therapeutics Corporation | $140.33 | 2021-2022 | |
| Edwards Lifesciences Corporation | $88.08 | 2024-2025 | |
| La Jolla Pharmaceutical Company | $85.62 | 2022 | |
| Merck Sharp & Dohme LLC | $74.53 | 2023-2024 | Verquvo, Winrevair |
| Novo Nordisk INC | $64.14 | 2022-2025 | Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.07 | 2022-2025 | Lifevest |
| Scpharmaceuticals INC. | $49.51 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $49.05 | 2023 | Camzyos |
| Amgen INC. | $48.04 | 2019-2025 | Repatha |
| Otsuka America Pharmaceutical, INC. | $41.78 | 2019 | |
| Lantheus Medical Imaging, INC. | $32.43 | 2019 | |
| Irhythm Technologies, INC. | $18.02 | 2024 | Zio Xt Patch, Zio Monitor |
| Viiv Healthcare Company | $17.81 | 2024 | Cabenuva |
| Sanofi-Aventis U.S. LLC | $13.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rola Khedraki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.